In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a price target of $140.00. The company’s shares closed yesterday at $27.21.
According to TipRanks, Rahimi is a 4-star analyst with an average return of 4.5% and a 36.15% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Soleno Therapeutics, and Savara.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arcturus Therapeutics with a $73.67 average price target.
ARCT market cap is currently $732.7M and has a P/E ratio of -26.13.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcturus Therapeutics (ARCT) Company Description:
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.
